

**A peer-reviewed version of this preprint was published in PeerJ on 8 February 2016.**

[View the peer-reviewed version](https://doi.org/10.7717/peerj.1671) (peerj.com/articles/1671), which is the preferred citable publication unless you specifically need to cite this preprint.

Blagec K, Romagnoli KM, Boyce RD, Samwald M. (2016) Examining perceptions of the usefulness and usability of a mobile-based system for pharmacogenomics clinical decision support: a mixed methods study. PeerJ 4:e1671 <https://doi.org/10.7717/peerj.1671>

# Examining perceptions of the usefulness and usability of a mobile-based system for pharmacogenomics clinical decision support: a mixed methods study

Kathrin Blagec, Katrina M Romagnoli, Richard D Boyce, Matthias Samwald

**Background.** Pharmacogenomic testing has the potential to improve the safety and efficacy of pharmacotherapy, but clinical application of pharmacogenetic knowledge has remained uncommon. Clinical decision support (CDS) systems could help overcome some of the barriers to clinical implementation. The aim of this study was to evaluate the perception and usability of a web- and mobile-enabled CDS system for pharmacogenetics-guided drug therapy – the Medication Safety Code (MSC) system – among potential users (i.e., physicians and pharmacists). Furthermore, this study sought to collect data on the practicability and comprehensibility of potential layouts of a proposed personalized pocket card that is intended to not only contain the machine-readable data for use with the MSC system but also human-readable data on the patient’s pharmacogenomic profile.

**Methods.** We deployed an emergent mixed methods design encompassing (1) qualitative interviews with pharmacists and pharmacy students, (2) a survey among pharmacogenomics experts that included both qualitative and quantitative elements and (3) a quantitative survey among physicians and pharmacists. The interviews followed a semi-structured guide including a hypothetical patient scenario that had to be solved by using the MSC system. The survey among pharmacogenomics experts focused on what information should be printed on the card and how this information should be arranged. Furthermore, the MSC system was evaluated based on two hypothetical patient scenarios and four follow-up questions on the perceived usability. The second survey assessed physicians’ and pharmacists’ attitude towards the MSC system. **Results.** In total, 101 physicians, pharmacists and PGx experts coming from various relevant fields evaluated the MSC system. Overall, the reaction to the MSC system was positive across all investigated parameters and among all user groups. The majority of participants were able to solve the patient scenarios based on the recommendations displayed on the MSC interface. A frequent request among participants was to provide specific listings of alternative drugs and concrete dosage instructions. Negligence of other patient-specific factors for choosing the right treatment such as renal function and co-medication was a common concern related to the MSC system, while data privacy and cost-benefit

considerations emerged as the participants' major concerns regarding pharmacogenetic testing in general. The results of the card layout evaluation indicate that a gene-centered and tabulated presentation of the patient's pharmacogenomic profile is helpful and well-accepted. **Conclusions.** We found that the MSC system was well-received among the physicians and pharmacists included in this study. A personalized pocket card that lists a patient's metabolizer status along with critically affected drugs can alert physicians and pharmacists to the availability of essential therapy modifications.

# Examining perceptions of the usefulness and usability of a mobile-based system for pharmacogenomics clinical decision support: a mixed methods study

Kathrin Blagec<sup>\*1</sup>, Katrina Romagnoli<sup>\*2</sup>, Richard D. Boyce<sup>2</sup>, and Matthias Samwald<sup>§1</sup>

<sup>1</sup>Section for Medical Expert and Knowledge-Based Systems; Center for Medical Statistics, Informatics, and Intelligent Systems; Medical University of Vienna, Vienna, Austria

<sup>2</sup>Department of Biomedical Informatics; University of Pittsburgh; Pittsburgh, PA, USA

## ABSTRACT

**Background.** Pharmacogenomic testing has the potential to improve the safety and efficacy of pharmacotherapy, but clinical application of pharmacogenetic knowledge has remained uncommon. Clinical decision support (CDS) systems could help overcome some of the barriers to clinical implementation. The aim of this study was to evaluate the perception and usability of a web- and mobile-enabled CDS system for pharmacogenetics-guided drug therapy – the Medication Safety Code (MSC) system – among potential users (i.e., physicians and pharmacists). Furthermore, this study sought to collect data on the practicability and comprehensibility of potential layouts of a proposed personalized pocket card that is intended to not only contain the machine-readable data for use with the MSC system but also human-readable data on the patient's pharmacogenomic profile

**Methods.** We deployed an emergent mixed methods design encompassing (1) qualitative interviews with pharmacists and pharmacy students, (2) a survey among pharmacogenomics experts that included both qualitative and quantitative elements and (3) a quantitative survey among physicians and pharmacists. The interviews followed a semi-structured guide including a hypothetical patient scenario that had to be solved by using the MSC system. The survey among pharmacogenomics experts focused on what information should be printed on the card and how this information should be arranged. Furthermore, the MSC system was evaluated based on two hypothetical patient scenarios and four follow-up questions on the perceived usability. The second survey assessed physicians' and pharmacists' attitude towards the MSC system.

**Results.** In total, 101 physicians, pharmacists and PGx experts coming from various relevant fields evaluated the MSC system. Overall, the reaction to the MSC system was positive across all investigated parameters and among all user groups. The majority of participants were able to solve the patient scenarios based on the recommendations displayed on the MSC interface. A frequent request among participants was to provide specific listings of alternative drugs and concrete dosage instructions. Negligence of other patient-specific factors for choosing the right treatment such as renal function and co-medication was a common concern related to the MSC system, while data privacy and cost-benefit considerations emerged as the participants' major concerns regarding pharmacogenetic testing in general. The results of the card layout evaluation indicate that a gene-centered and tabulated presentation of the patient's pharmacogenomic profile is helpful and well-accepted.

**Conclusions.** We found that the MSC system was well-received among the physicians and pharmacists included in this study. A personalized pocket card that lists a patient's metabolizer status along with critically affected drugs can alert physicians and pharmacists to the availability of essential therapy modifications.

**Keywords:** Pharmacogenetics; Individualized Medicine; Decision Support Systems, Clinical; User studies; Mixed methods studies

## INTRODUCTION

In the past two decades, pharmacogenomics has become a promising area in the field of personalized medicine. There is a growing body of literature that emphasizes the influence of genetic variants on the rate of adverse drug events or drug inefficacy and several working groups have been formed with the aim of developing and publishing pharmacogenetics-based drug dosing guidelines (Caudle et al., 2014; Swen et al., 2011; Pirmohamed et al., 2013). Nevertheless, clinical application of pharmacogenetic knowledge has been slow and is largely reserved to specialized centers and clinical trials (Hoffman et al., 2014; Gottesman et al., 2013; O'Donnell et al., 2014; Pulley et al., 2012). One of the reasons for this might be physicians' lack of education in pharmacogenetics and consequently lack of confidence in dealing with such information (Haga et al., 2012).

Pharmacogenomic clinical decision support (CDS) systems, if well-designed, could help to overcome these challenges. Studies suggest that physicians have a positive attitude towards CDS systems, appreciating them as tools to manage and make optimal use of the large amounts of complex information that they are often confronted with (Varonen et al., 2008; Zaidi et al., 2008). Also, there is evidence that the implementation of CDS systems can positively influence health care processes (Jaspers et al., 2011; Bright et al., 2012). Finally, the amount of pharmacogenomic knowledge available in structured formats that can be utilized for CDS is improving (Boyce et al., 2013). However, clinical implementation of CDS systems is often hindered by usability issues, lack of user acceptance and uncertainty on how to integrate such systems efficiently into existing and diverse workflows (Kawamoto, 2005). These issues are especially salient in settings where sophisticated CDS systems with the ability of actively generating PGx-based alerts during order entry are lacking.

The purpose of this study is to evaluate the perception of potential users (i.e., physicians and pharmacists) on the usefulness and usability of a flexible mobile-based clinical decision support system for pharmacogenetics-guided drug therapy that can be easily integrated into existing care processes and infrastructures: the Medication Safety Code (MSC) system. The MSC system makes it possible to store pharmacogenomic patient data in compact two-dimensional quick response (QR) codes which can be decoded and interpreted by common smartphones and other devices. The QR code can be included in paper-based lab reports or can be printed on personalized cards. Patients can carry these cards in their wallets and display them to medical professionals when pharmacotherapy is initiated or altered. After scanning the QR code, the medical professional is led to a website that provides decision support messages customized to the pharmacogenomic profile of the patient. The website provides information on all drugs for which clinically significant and actionable pharmacogenomic findings are available, placing drugs for which the patient's specific genetic profile would indicate a deviation from standard therapy on top. Links below each recommendation allow medical professionals to explore full guideline texts and original references at the Pharmacogenomics Knowledgebase (PharmGKB) website. A screenshot of the MSC interface is shown in Figure 2. More detailed descriptions of the Medication Safety Code service and the underlying technology are available from previous publications (Samwald and Adlassnig, 2013; Miñarro-Giménez et al., 2014).

The goal of this study was to (1) evaluate the perception and usability of the MSC system among potential users (i.e. physicians and pharmacists) and to (2) collect data on the practicability and comprehensibility of potential layouts of the proposed personalized pocket card.

## METHODS

### Study design

We chose an emergent mixed method design encompassing qualitative interviews and quantitative surveys with qualitative elements to allow for a deeper insight into the perception and usability of the MSC system among potential user groups. A multi-method approach was adopted because of its complementary effect in detecting potential usability issues and other barriers that might hinder the implementation of such a system (Walji et al., 2014). The study was conducted in three consecutive phases between June 2014 and September 2015 that built on one another: (1) An initial qualitative interview study among pharmacists and pharmacy students, (2) a web-based survey among PGx experts coming from a wide range of relevant disciplines ("Survey A"), (3) a web-based survey among physicians and pharmacists ("Survey B"). After each stage, an analysis and interpretation of the collected data was performed, followed by an adaptation phase in which the results were used to inform the further development and evaluation process of the

101 MSC system (see Figure 1).




Figure 1. Study design

## 102 Medication Safety Code system

### 103 User interface

104 A demo version of the MSC decision support system for a fictional patient (CYP2D6 ultrarapid metabolizer, TPMT poor metabolizer) was used for each of the interviews conducted during the study and for both web-based surveys. In the interviews, participants were presented with a patient scenario in which codeine was prescribed to a fictional patient named "Marilyn" (CYP2D6 ultrarapid metabolizer). Individuals that are CYP2D6 ultrarapid metabolizers have additional copies of the CYP2D6 gene leading to an increased metabolism of several drug substances and consequently a higher chance of adverse drug reactions or drug inefficacy. For codeine, the CYP2D6 ultrarapid metabolizer phenotype is associated with higher rates of adverse drug events and therefore guidelines suggest to avoid prescribing codeine to individuals with this phenotype. For both online surveys, two hypothetical patient scenarios were presented (prescription of codeine for a CYP2D6 ultrarapid metabolizer and prescription of azathioprine for a TPMT poor metabolizer; see Table 1). Patients that are TPMT poor metabolizers are at higher risk of developing life-threatening myelosuppression when treated with standard doses of thiopurine drugs such as azathioprine, 6-mercaptopurine or 6-thioguanine. In total, the system thus highlighted critical recommendations for four drugs, i.e., codeine, azathioprine, mercaptopurine and thioguanine (Figure 2). Within the first adaptation phase, the MSC UI was split into two different versions to avoid confusion about displaying two different guidelines for the same drug: a "U.S. version" displaying the CPIC guidelines and a "European" version displaying the DPWG guidelines (see Table 6).

### 121 Pocket card layouts

122 Besides the QR code and some personal information (i.e., patient name, date of birth, card number, issue date, name of the providing laboratory), the pocket card is intended to contain human-readable information on the patient's pharmacogenomic profile to quickly determine if relevant, actionable genetic variants are actually present. For this study, five different mock-ups of potential card layouts were created to facilitate the visualization of how such information could be represented on the card (see Figure 3).

## 127 Interviews

### 128 Data collection

129 The interviews were conducted as part of a larger-scale study carried out by KR that focused on pharmacists' general need of pharmacogenomic information. This study was carried out in an academic health system in Western Pennsylvania and an associated private nursing home prescription benefits management organization. Out of the original sample of 14, a convenience sample of eight participants (five clinical pharmacists and three pharmacy students) were recruited for the MSC usability study and interviewed. The study was classified as exempt by the University of Pittsburgh institutional review board.

135 An information leaflet listing key facts about the MSC system was given to each participant at the outset of the interview (see Additional file 1). Each interviewee was presented with a patient scenario in which codeine was prescribed to the fictional patient named "Marilyn". They were then asked to

### Patient scenario 1

A 35-year-old patient suffering from severe, steroid-refractory Crohn's disease with extraintestinal manifestations is to be treated with azathioprine. He has pharmacogenomic test results available, identifying him to be a TPMT poor metabolizer. Solely based on these test results and the recommendations provided by the MSC (regardless of other factors such as renal function or drug interactions), what would you recommend for this patient? (more than one answer possible; TPMT: thiopurine S-methyltransferase, an enzyme)

- a) Prescribe azathioprine at normal dosage
- b) Prescribe azathioprine at reduced dosage
- c) Prescribe a different drug substance

### Patient scenario 2

A 19-year-old patient suffering from post-operative pain is to be treated with codeine. She has pharmacogenomic test results available, identifying her to be a CYP2D6 ultrarapid metabolizer. Solely based on these test results and the recommendations provided by the MSC (regardless of other factors such as renal function or drug interactions), what would you recommend for this patient? (more than one answer possible)

- a) Prescribe codeine at normal dosage
- b) Prescribe a different drug substance, e.g. morphine
- c) Prescribe a different drug substance, e.g. tramadol

**Table 1.** Patient scenarios used for the MSC evaluation

138 make a recommendation based on Marilyn's genetic profile (CYP2D6 ultrarapid metabolizer) and the  
139 pharmacogenetic decision support messages displayed in the MSC user interface.

140 The second part of the interview followed a semi-structured interview guide to explore the participants'  
141 general perception of the MSC system and its appearance, their concerns about the MSC system, potential  
142 barriers to incorporation of such a system into their workflows, and questions about whether the MSC  
143 provides sufficient information to make them feel confident in giving a recommendation (see Additional  
144 file 2).

### 145 Data analysis


146 Interviews were audio-recorded, transcribed verbatim and analyzed for themes. The length of the  
147 interviews ranged between four and fourteen minutes with a mean length of approximately ten minutes.  
148 The transcripts were qualitatively coded by one researcher based on the themes covered by the interview  
149 guide. In a second step, categories were inductively split up further into specific sub-categories to identify  
150 recurrent themes in the participants' answers. Results were discussed among co-authors.

### 151 Web-based surveys

#### 152 Design

153 We conducted two separate online surveys aiming at two different target groups to capture a breadth of  
154 viewpoints: Survey A was addressed at PGx experts from various disciplines while Survey B specifically  
155 focused on end users (i.e., physicians and pharmacists) without particular expertise in PGx. The decision of  
156 splitting the surveys and restricting the target group of Survey A to PGx-experienced professionals instead  
157 of conducting one all-encompassing survey was based on the assumption that sound PGx knowledge is  
158 indispensable for giving informed feedback on how and what human-readable PGx information should  
159 be represented on the pocket card. The main aim of Survey A therefore was to get feedback from  
160 pharmacogenomics-experienced professionals on potential layouts of the MSC pocket card. For this  
161 purpose, five layout mock-ups that had to be rated from 1 (not practical) to 5 (very practical) were  
162 presented to the participants. Additionally, this part of the questionnaire contained 4 multiple choice  
163 questions and free text fields asking the participants which information should be printed on the card and





**Figure 2.** Two screenshots of the MSC interface. Patient-specific guidelines for codeine are shown for a hypothetical patient who has pharmacogenetic test results available that identify him as “CYP2D6 ultrarapid metabolizer” and “TPMT poor metabolizer”. The screenshots depict the version of the user interface that was used during the pilot interviews with pharmacists.

164 how this information should be presented.

165 In the second part of Survey A, the MSC user interface was evaluated based on two hypothetical use  
 166 cases and six follow-up questions including free-text fields.

167 Survey B, on the other hand, focused on evaluating physicians’ and pharmacists’ attitudes towards the  
 168 MSC system based on two hypothetical patient scenarios and 25 follow-up questions including a 16-item  
 169 MSC evaluation Likert scale encompassing the following four subscales: (1) usability, (2) trustworthiness,  
 170 (3) usefulness, (4) workflow integration. This scale was based on the System Usability Scale (SUS)  
 171 (Brooke, 1996) but extended based on the results of the preceding interview study and our specific target  
 172 group (e.g., we extended the scale with 4 items regarding workflow integration which was identified as a  
 173 probable implementation barrier in the preceding interviews). Furthermore, participants’ awareness of  
 174 and experience with PGx and clinical decision support systems were assessed.

175 The patient scenarios used for both surveys are shown in Table 1. In both surveys, participants could  
 176 choose if they want to test the “European” (displaying the DPWG guidelines) or the “U.S.” version  
 177 (displaying the CPIC guidelines). The questions on the patient scenarios were clearly answerable with



# Front side layout



The Medication Safety Code initiative



→ What is the Medication Safety Code? A QR code that captures patient-specific data on genetic variants in important pharmacogenes.

→ What can you do with it? After scanning the QR code on the left with a standard smartphone, you are led to a website that displays patient-specific drug dosing recommendations.


→ Who developed it? It was developed at the Medical University of Vienna with the aim of facilitating individualized drug therapy.

Laboratory contact details

- Phone number
- Address

For more information, please visit [www.safety-code.org](http://www.safety-code.org)

# Back side layout option 1



The Medication Safety Code initiative


**Critical drug substances (modification recommended!)**

→ Amitriptyline	↓ Halopridol	→ Thioguanine
↓ Aripiprazole	→ Imipramine	→ Trimipramine
↓ Azathioprine	↓ Mercaptopurine	→ Venlafaxine
→ Clomipramine	↓ Metoprolol	
→ Codeine	→ Nortriptyline	
→ Desipramine	↓ Propafenone	
→ Doxepin	• Tamoxifen	

**Genes tested**  
CYP2C19, CYP2C9, CYP2D6, CYP3A5, DPYD, SLCO1B1, TPMT, UGT1A1, VKORC1,

**Legend**  
↓ higher dose required  
↓ lower dose required  
→ alternative drug recommended  
• other recommendation

# Back side layout option 2



The Medication Safety Code initiative


**Critical drug substances (modification recommended!)**

Δ Amitriptyline	• Halopridol	• Thioguanine
• Aripiprazole	• Imipramine	Δ• Trimipramine
• Azathioprine	• Mercaptopurine	• Venlafaxine
Δ• Clomipramine	• Metoprolol	
• Codeine	Δ• Nortriptyline	
Δ• Desipramine	• Propafenone	
Δ• Doxepin	• Tamoxifen	

**Genes tested**  
CYP2C19, CYP2C9, CYP2D6, CYP3A5, DPYD, SLCO1B1, TPMT, UGT1A1, VKORC1,

**Legend**  
Δ Ultrarapid metabolizer  
□ Intermediate metabolizer  
• Poor metabolizer  
• other

# Back side layout option 3



The Medication Safety Code initiative


**Critical drug substances (modification recommended!)**

Amitriptyline	Desipramine	Metoprolol	Trimipramine
Aripiprazole	Doxepin	Nortriptyline	Venlafaxine
Azathioprine	Halopridol	Propafenone	
Clomipramine	Imipramine	Tamoxifen	
Codeine	Mercaptopurine	Thioguanine	

**Deviant phenotypes**  
CYP2C19 Intermediate metabolizer  
CYP2D6 Ultrarapid metabolizer  
TPMT Poor metabolizer

**Tested genes**  
CYP2C19, CYP2C9, CYP2D6, CYP3A5, DPYD, SLCO1B1, TPMT, UGT1A1, VKORC1


# Back side layout option 4



The Medication Safety Code initiative

Gene	Status
CYP2D6	Poor metabolizer
CYP2C9	Normal
CYP2C19	Ultrarapid metabolizer
CYP3A5	Normal
TPMT	Poor metabolizer
DPYD	Normal
SLCO1B1	Normal
VKORC1	Normal

# Back side layout option 5



The Medication Safety Code initiative

Gene	Status	Critical drug substances (modification recommended!)
CYP2D6	Ultrarapid metabolizer	amitriptyline, clomipramine, codeine, desipramine, imipramine, nortriptyline, trimipramine, haloperidol, metoprolol, paroxetine, propafenone, risperidone, tramadol
CYP2C19	Intermediate metabolizer	amitriptyline, clomipramine, clopidogrel, desipramine, doxepin, nortriptyline, trimipramine
TPMT	Poor metabolizer	azathioprine, mercaptopurine, thioguanine
Normal: CYP2C9, CYP3A5, DPYD, SLCO1B1, VKORC1		

**Figure 3.** Card layout mock-ups: The front side contains the QR code and general information. The back side is intended to contain a summary of the patient's pharmacogenomic profile to allow for a quick decision if it is worth to scan the QR code.

both versions. Furthermore, participants could choose between accessing the demo site by either scanning the QR code on the screen or clicking on a link. Both questionnaires also contained a demographics section that included questions regarding participants' field of work and work experience.

Prior to data collection, the surveys were pre-tested by 4 individuals with medical background to

determine and eliminate any weaknesses and ambiguities of the questionnaire. Overall, 16 issues and suggestions for improvements were identified during the pre-test phase and taken into account for revising the questionnaires. Ethical approval for both surveys was obtained from the ethics committee of the Medical University of Vienna (No. 1417/2015).

### **Data collection**

For Survey A, PGx-experienced professionals were recruited via e-mail through personal contacts and by distribution via the AMIA Genomics and Translational Bioinformatics (Gen-TBI) Working Group and the PharmGKB network. For Survey B, physicians and pharmacists were recruited via e-mail invitations and through advertisements in professional networks. The first 10 respondents of Survey A and the first 40 respondents of Survey B were eligible for a \$17/15€ Amazon voucher.

### **Data analysis**

The card layout ratings of Survey A were analyzed descriptively and tested for statistically significant differences using Wilcoxon signed-rank tests. For the MSC evaluation instrument, summing up the subscale scores formed the instruments' total score. Basic descriptive statistical measures were calculated for each MSC evaluation subscale and for the total scale. Reliability of the subscales was calculated using Cronbach's alpha. (Lee J. Cronbach, 1951) Besides a descriptive analysis of the evaluation results, non-parametric tests (Mann Whitney U-test and Kruskal Wallis test) were used to test for statistically significant differences in the total MSC evaluation score based on profession, awareness of and experience with clinical decision support systems and genome-guided prescribing. Furthermore, a content analysis of the text box questions, such as comment fields, was conducted for both surveys. Statistical analyses were performed using SPSS 20.

## **RESULTS**

### **Demographics**

#### **Interviewed pharmacists**

All five pharmacists were female and aged between 36 and 50. Two of them had been working as pharmacists between five and 15 years, another two between 16 and 25 years and the remaining one stated having less than five years of work-experience. The participants were either working as clinical consultants in nursing homes (n=3), clinical pharmacists in family practice (n=1) or as out-patient pharmacists/director of pharmacy residency and advanced practice (n=1). Out of the five working pharmacists, two stated that they had already been professionally exposed to pharmacogenomics. However, none of them had ever been in contact with patients that had pharmacogenetic test results available. Furthermore, none of them had ever recommended pharmacogenetic testing to a patient so far. The three interviewed students were aged between 18 and 35, two were male and one was female. All of them stated that they had learned about the application of pharmacogenetics in pharmacy school didactic coursework and had participated in research involving the presentation of pharmacogenetic information. None of them ever had previous contact with patients with pharmacogenetic test results.

#### **PGx experts in Survey A**

By the end of the survey period, data had been collected from 63 individuals. Out of those, 9 respondents were excluded because they did not match the target group of "PGx experts" (e.g., participants who stated being pharmacy or medical students were excluded). Out of the remaining 54 respondents, 44,4% were female (see Table 2). Physicians and pharmacists accounted for 33,3% and 31,4% of the participants, respectively. The remaining respondents consisted of researchers (22,2%) and PGx experts from other disciplines (e.g., software developers) (13%). The majority of respondents (90,7%) were US residents, 5,6% were European residents and the remaining 3,7% were located in other regions of the world (i.e., New Zealand and Egypt).

#### **Physicians and pharmacists in Survey B**

A total of 450 physicians and pharmacists were invited via e-mail. Out of those invitations, 28 were undeliverable. 26 of the invited individuals completed the questionnaire (response rate 6,2%). Advertisements in professional networks of the co-authors accounted for 17 additional respondents, resulting in a total number of 43 participants. Of these 43 participants, 4 had to be excluded. Out of the remaining 39 respondents, 11 (28,2%) were pharmacists (see Table 2). The overwhelming majority of participants were

	Survey A		Survey B	
<b>Gender</b>	n	%	n	%
Female	24	44,4	15	38,5
Male	30	56,6	24	61,5
<b>Age</b>	n	%	n	%
20-29	10	18,5	17	43,6
30-39	24	44,4	12	30,8
40-49	10	18,5	4	10,3
50-59	7	13,0	4	10,3
60 or older	3	5,6	2	5,1
<b>Profession</b>	n	%	n	%
Pharmacist	18	33,3	11	28,2
Physician	17	31,5	28	71,8
Clinician at hospital	15	27,8	4	10,3
Doctor-in-training	-	-	12	30,8
Resident doctor	1	1,9	11	28,2
Other	1	1,9	1	2,6
Researcher	12	22,2	-	-
Other	7	13,0	-	-
<b>Country</b>	n	%	n	%
USA	49	90,7	-	-
Austria	-	-	17	43,6
Germany	-	-	18	46,2
Other	5	9,3	4	10,2
<b>Years in work field</b>	n	%	n	%
>20 years	8	14,8	4	10,3
11-20 years	13	24,1	3	7,7
6-10 years	14	25,9	6	15,4
0-5 years	19	35,2	26	66,6
<b>Total</b>	54	100	39	100

**Table 2.** Participant demographics of Survey A and B. The participant demographics of the interviewed pharmacists and pharmacy students (n=8) are described in the text.


from Austria and Germany (43,6% and 46,2%, respectively). 56,4% and 69,2% of the participants stated that they were aware of genome-guided prescribing and clinical decision support systems, respectively.

Over half of the respondents indicated that they were at least sometimes using clinical decision support systems (56,4% sometimes and 5,1% often). In contrast, only 30,8% of the participants were sometimes performing genome-guided prescribing, whereas the remaining 69,2% were never performing genome-guided prescribing (see Figure 4).

## Evaluation of the MSC system

### Patient scenarios

All of the eight interviewees came to the conclusion to avoid prescribing codeine to the fictional patient Marilyn due to her CYP2D6 ultrarapid metabolizer phenotype. Two out of the eight participants named a specific drug (i.e., Tylenol [active ingredient: Acetaminophen] and Morphine) which they would recommend to prescribe as an alternative to codeine to Marilyn based on the guideline text. Six interviewees formed their conclusions solely based on the information displayed by the MSC user interface. The remaining two participants would have preferred to additionally visit the references prior to making their final recommendation. However, this was not possible in the controlled study setting.



**Figure 4.** Use of CDS systems and genome-guided prescribing among physicians and pharmacists; CDS: Clinical decision support, GGP: genome-guided prescribing

	Survey A	Survey B
Patient scenario 1	n (%)	n (%)
*Prescribe azathioprine at reduced dosage	32 (45,1)	20 (42,6)
*Prescribe a different drug substance	30 (42,3)	25 (53,2)
Prescribe azathioprine at normal dosage	9 (12,7)	2 (4,3)
Patient scenario 2	n (%)	n (%)
*Prescribe a different drug substance, e.g. morphine	40 (72,7)	25 (64,1)
Prescribe codeine at normal dosage	8 (14,6)	5 (12,8)
Prescribe a different drug substance, e.g. tramadol	7 (12,7)	9 (23,1)

**Table 3.** Results of the patient scenarios in Survey A (PGx experts) and Survey B (physicians and pharmacists); Recommended treatments according to the DPWG and CPIC guidelines are marked with asterisks.

Likewise, almost all of the respondents of Survey A and B decided to treat patient 1 in accordance with the DPWG or CPIC guidelines. Interestingly, 12,7% of the PGx experts decided to prescribe azathioprine at normal dosage regardless of the patient's TPMT poor metabolizer phenotype. Among the participants of Survey B only 2 individuals (4,3%) would have prescribed the standard dosage of azathioprine (see table 3). In patient scenario 2, 72,7% of the PGx experts and 64,1% of the physicians and pharmacists of Survey B would have acted in accordance with the guidelines.

#### General perception

The interviewees' reaction to the MSC user interface was consistently positive. Three-quarters of the interviewed participants explicitly mentioned the appearance (i.e., layout, formatting and drug categorization) of the MSC interface as appealing. Likewise, across both surveys the majority of participants agreed (57,6%) or strongly agreed (9,8%) that the MSC UI design was appealing. Half of the interviewed pharmacists stated that they appreciated the conciseness and ease of use of the MSC interface. Other themes that were perceived positively by at least two of the interviewed pharmacists were the links to the references and the fact that a recommendation for an alternative drug was stated in the guideline text for codeine. Two of the interviewed pharmacists liked the fact that guidelines by two different groups were provided by the MSC, while on the other hand three participants considered this as negative and confusing.

"For codeine both of the guidelines are saying that there is a problem but if there is not an agreement on that, what would I consult next?" – Pharmacy student 1

Almost all of the interviewees showed great interest in visiting the references (i.e., PharmGKB website) by clicking on the "Show guideline website" button. Across both surveys, half of the overall participants (50,5%) stated that they had also explored the PharmGKB website.

Table 4 presents the descriptive statistical measures for each subscale and in total for the MSC evaluation among physicians and pharmacists in Survey B. On average, the participating physicians rated the MSC system higher, but not significantly higher than the participating pharmacists (see Table 5). Awareness of and prior experience with CDS systems and genome-guided prescribing did not significantly influence the participants attitude towards the MSC system. 46,2% of the respondents tested the MSC system by scanning the QR code that led to the demo website. Over half of the participating physicians and pharmacists confirmed that they would appreciate the availability of an additional booklet containing all relevant PGx recommendations to be able to look them up without having to use a computer or mobile phone.

Scale	# Items	n	Median	IQR	Mean	SD	Alpha
Usability	4	39	11	5,0	10,6	3,1	0,8
Trustworthiness	4	39	10	4,0	10,5	2,4	0,7
Usefulness	4	39	12	3,0	11,4	2,1	0,7
Workflow integration	4	39	10	4,0	9,9	2,3	0,5
<b>Total scale</b>	<b>16</b>	<b>39</b>	<b>42</b>	<b>11</b>	<b>42,3</b>	<b>8,1</b>	<b>0,9</b>

**Table 4.** Descriptive statistical parameters and Cronbach's alpha for the MSC evaluation subscales and total scale. Higher scores represent more positive responses. All items were 5-point (0-4) Likert items. The maximum scores for each subscale and in total were 16 and 64, respectively;

	MSC total score		
Independent variable	Mean (SD)	Median (IQR)	p-value
Awareness of GGP			
Aware	41,3 (9,2)	41,0 (13)	0,069 (NS) <sup>a</sup>
Unaware	43,7 (6,5)	45,5 (7)	
Awareness of CDSS			
Aware	41,5 (9,1)	41,0 (13)	0,133 (NS) <sup>a</sup>
Unaware	44,2 (7)	45,5 (7)	
Use of GGP			
Never	43,0 (7,2)	45,0 (8)	0,142 (NS) <sup>a</sup>
Sometimes	40,8 (10,1)	37,0 (7)	
Often	-	-	
Use of CDSS			
Never	45,1 (9,2)	46,0 (13)	0,215 (NS) <sup>b</sup>
Sometimes	40,4 (7,3)	40,0 (11)	
Often	43,5 (2,1)	43,5 (-)	
Occupation			
Physicians	43,7 (8,6)	42,5 (11)	0,089 (NS) <sup>a</sup>
Pharmacists	38,8 (5,5)	37,0 (10)	

**Table 5.** Comparison of scores for the total scale between different subgroups of respondents. Higher scores represent more positive responses. Maximum score: 64; <sup>a</sup> Mann Whitney U-Test, <sup>b</sup> Kruskal Wallis Test; GGP: genome-guided prescribing; CDSS: clinical decision support services; NS: not statistically significant; statistical significance at 0.05.

#### Workflow integration and balance between too little information and information overload

Seven out of the eight interviewees stated that the MSC system would fit well into their workflow, one participant expressed concerns regarding time as the limiting factor for a successful incorporation. Lack of time was also seen as a probable barrier by two others of the interviewed pharmacists and pharmacy students.

“Probably time, if it's really busy at the pharmacy this might be something that's overlooked, especially if it's not mandatory, the pharmacist has to do it then it just might be overlooked.”

286 – Pharmacy student 2

287 Among the participating physicians and pharmacists of Survey B, the median score for the workflow  
288 integration subscale was 10 (maximum score 16, see Table 4). Regarding integration into workflow, a  
289 common wish amongst the interviewed pharmacists was the integration of the information provided by  
290 the MSC into the patient chart after scanning the QR code once or incorporation into the electronic health  
291 record/ computerized provider order entry (CPOE) system.

292 “I need it to be in the chart, because the next time, I don’t want to have to look it up every  
293 single time” – Clinical pharmacist 4

294 Three-quarters of the interviewed pharmacists and pharmacy students agreed that the MSC system  
295 provided enough information for making them feel comfortable in giving a recommendation about a  
296 drug/phenotype combination. The median score for the trustworthiness scale in Survey B was 10 (see  
297 Table 4). One of the interviewed pharmacists said that they would prefer to have more background  
298 information in case they are asked by a physician. However, two interviewees felt that the amount of text  
299 might already be too large to read for a physician/pharmacist in a busy setting and one of them suggested  
300 the highlighting of keywords to resolve this issue. One participant indicated that the guidelines displayed  
301 by the MSC make them confident to recommend avoiding codeine but not in terms of alternative drugs. A  
302 concrete listing of alternative therapy options was also something one quarter of the interviewees found  
303 lacking on the MSC interfaces. Likewise, one PGx experienced physician commented on his choice in the  
304 first patient scenario in Survey A as follows:

305 ”Would also follow the recommended dosing interval and monitoring instructions. I would  
306 potentially use an alternative medication, but the alert doesn’t tell me what alternatives would  
307 be appropriate (nor did the guidelines website).”

308 Three interviewees indicated that they would not only appreciate a listing of alternative drugs but also a  
309 link to the respective dosing guidelines or an integrated dosage conversion tool. Furthermore, some of the  
310 participants stated that they would have liked the listed adverse drug events to be more specific.

311 “Toxicity is a very broad term. A lot of side effects that can be associated with it so maybe if  
312 there is a section that indicates specifically a tab like three most common toxicities associated  
313 with codeine use in ultrarapid metabolizers that would give me more a reassurance and  
314 confidence”- Pharmacy student 2

315 A common issue amongst half of the interviewees was confusion and uncertainty about the two different  
316 guideline publishing consortia; especially the Dutch Pharmacogenetics Working Group (DPWG) (Swen  
317 et al., 2011) was so far unknown to them. One participant also commented that they wanted to know  
318 more about the origin and evidence of the guidelines, i.e., if they were derived from human or animal  
319 studies. However, in response to the question “Is there information you would like, but cannot find using  
320 the Safety Code system?” some participants also considered that it might be counter-productive to include  
321 additional information unless it is absolutely necessary and would not create the burden of excessive  
322 information.

323 “The more information you include, the more difficult it gets to weed through and tell what’s  
324 pertinent” – Clinical pharmacist 1

### 325 **General concerns**

326 Five different concerns towards the implementation of a system like the MSC emerged from the analysis.  
327 Three participants expressed concerns regarding data privacy. Skepticism towards technology and possible  
328 change aversion of professionals were also mentioned. Some interviewees expressed doubts regarding the  
329 cost-benefit ratio of implementing such a system and one participant mentioned the potential negligence  
330 of other factors relevant for making a therapy decision as something he would be concerned about.

331 “The concern is there’s other factors besides just pharmacogenetics that dictate the kind of  
332 drug the patient should get, it’s not the only factor that determines what a patient should get  
333 ... if they’ve gotten this before at a reasonable dose then it’s probably something that, and  
334 they didn’t experience any side effects then it might be something that they can keep using” –  
335 Pharmacy student 2



### Adaptations

During the evaluation process, several issues and suggestions for improvement of the MSC Interface were identified. A list of all issues that led to changes of the interface during the three adaptation phases can be found in Table 6.

Phase	Issue	Adaptation in response to the issue
1	Confusion and uncertainty about displaying guidelines from two different consortia	The interface was split in two different versions: a "U.S. version" displaying the CPIC guidelines and a "European version" displaying the DPWG guidelines
2	Confusion about the headings and sections "critical" and "all"	The "all guidelines" list was removed so that the interface now displays only the critical drugs. The heading was changed from "critical" to "critical guidelines for this patient".
2	Ambiguity whether the "last guideline update" date refers to the last MSC update or the update on sources (e.g. the latest version of CPIC guideline)	"Last guideline update" was changed to "date of evidence"

**Table 6.** Issues detected during the study and modifications made in response in the adaptation phases

### Card layout evaluation

#### Ratings and comments

Table 7 shows the descriptive statistical measures for all five layouts split by professional group and in total. Overall, layout 1 and 5 received the highest and significantly better ratings than the other layouts ( $p=0,02$  and  $p=0,003$ , respectively). A common point of critique regarding layout 1 was that the arrow system is too confusing and too difficult to follow. One participant also argued that with the arrow system prescribers might be tempted to adjust the dosage by themselves without looking up the recommended dosage. Out of all layouts, layout five had the highest number of positive comments, but also several concerns and suggestions for minor changes were expressed by the respondents. These included suggestions to replace the term "normal" in the bottom line with "wild-type" or "extensive metabolizer" and to add a statement that the drugs listed are not all inclusive. One participant felt that layout 5 might be confusing for some prescribers because the drugs are sorted by gene and therefore some drugs are listed in two different rows. Across all layouts, a common concern among participants was that the PGx information on the card (especially affected drugs) would become out of date soon and that the card would have to be reprinted frequently.

	Clinicians		Pharmacists		Researchers		Others		Overall	
	Median	IQR	Median	IQR	Median	IQR	Median	IQR	Median	IQR
L1	4	2	3	2	4	2	5	1	4	1
L2	4	1	2	2	3	2	3	1	3	2
L3	4	2	2,5	2	3	2	2	3	3	2
L4	4	2	2,5	2	1,5	3	1	1	2	3
L5	4	0	4	2	3	1	3	2	4	1

**Table 7.** Descriptive statistical measures of the card layout ratings by professional group and in total; L: Layout, IQR: Interquartile range

#### Other information that should be printed on the card

The majority of participants confirmed that patients' drug allergies based on medical history and laboratory contact details would be useful additional information that should be printed on the card (79,6% and 68,5%, respectively). The other possible selections "signature of laboratory head" and "patient signature" were less frequently chosen (13,0 % and 16,7 %, respectively). Other suggestions given through the free-text fields were: "primary care physician", "nature of allergic reaction", "social security number",



current medication list and "revision/update cycle". Furthermore, one of the participants commented that information on drug allergies should not be printed on the card but should be captured in the QR code.

## DISCUSSION

### Principal results

The main goal of this study was to evaluate and inform the further development of a mobile-based clinical decision support system for pharmacogenomics that can be deployed in various health care settings regardless of the availability of advanced and compatible CPOE systems. Overall, our results indicate that the MSC system is perceived positively by the majority of physicians and pharmacists across all investigated aspects (i.e., usability, trustworthiness, usefulness and feasibility of workflow integration). While we did not find any statistically significant differences in the attitudes towards the MSC system according to profession, awareness of and experience with clinical decision support systems and genome-guided prescribing, this could have been fostered by the small scale of our study. The majority of participants were able to respond adequately to the patient scenarios indicating that the MSC interface presents information pertinent to decision-making in a user-friendly way. However, the second patient scenario generated a notable fraction of answers that are not in accordance with the recommendations made in the relevant guidelines. Based on participant comments, these can partly be explained by some physicians answering the question based on their clinical experience rather than solely on the displayed recommendation. Nevertheless, in other cases the reason remains unclear. The somewhat higher fraction of diverging answers in scenario 2 than in scenario 1 might point to a problem in the wording of the guideline itself.

During this study we furthermore identified several needs and suggestions for improvement of the MSC system, such as the confusion arising from displaying multiple and potentially differing recommendations from different guidelines. We pragmatically decided to split the UI into two versions to avoid confusion stemming from this issue in the subsequent evaluation phases. Ideally, only a single recommendation should be displayed, which—in case of the availability of multiple guidelines from different consortia—could also be based on a synthesis of available recommendations.

While one of the main advantages of the MSC system lies in its ability to implement pharmacogenomic CDS in settings where adequate IT infrastructure such as Computerized Physician Order Entry (CPOE) systems and Electronic Health Records (EHRs) are lacking, the findings from our qualitative interviews emphasize the need for such a system to be able to communicate with or to be integrated into existing systems to accomplish optimal work flow incorporation in various health care settings. Furthermore, our study points out that a listing of alternative drugs could be helpful to save time in the drug prescribing process and consequently increase physicians' and pharmacists' confidence in using the system.

Additionally, our study revealed a wish for the guidelines to be more specific (e.g., state concrete drug dosages or include a dosage converting tool) among the participants. However, displaying concrete drug dosages adapted only to the patient's pharmacogenomic profile might also nourish an often mentioned concern: the negligence of other factors relevant for providing an optimal drug therapy, such as renal function or co-medication. Being able to include all of the relevant contextual factors for treatment would be the ideal situation but would once again require the existence of a sophisticated and mature health IT infrastructure—a requirement that is currently lacking in many European countries.

Other concerns that emerged from the interviews referred to pharmacogenetic testing in general: the unclear cost benefit-ratio and data privacy concerns. While positive influence on patient outcome as well as cost-effectiveness of pharmacogenetics-guided drug therapy has been demonstrated for several drug substances, the situation for other drugs indeed remains unclear or conflicting. (Verhoef et al., 2015; Thompson et al., 2014; Lala et al., 2013; Olgiati et al., 2012) A pre-emptive pharmacogenetic testing approach could increase efficiency and reduce testing costs at the same time. (Schildcrout et al., 2012)

Despite the Genetic Information Nondiscrimination Act (GINA) and the Health Insurance Portability and Accountability Act (HIPAA) and similar policies in European countries, concerns towards data privacy are still common when it comes to pharmacogenetic testing. Concerns that health insurance providers might get access to genetic test results are widespread and suggest a need for education about legal and regulatory backgrounds as well as about the significance of testing for variations in drug metabolism enzymes as opposed to testing for risk of disease. (Tuteja et al., 2013)

Finally, the results of this study informed the development process of a prototypical pocket card that enables the widespread use pharmacogenomic data and decision support across different health care

settings. Our findings indicate that a gene-centered and tabulated presentation of the patient's pharmacogenomic profile on the pocket card is considered most helpful to call a physician's or pharmacist's attention to a patient being, e.g., a poor metabolizer and being in potential need for tailored therapy. Furthermore, our results emphasize the need for information transparency on the source of the pharmacogenomic data (i.e., tested variants, laboratory contact details) to make such a system valuable for and accepted among pharmacogenomics professionals.

## Related work

In recent years, there has been an increasing amount of literature on the development, implementation and evaluation of pharmacogenomic CDS systems. Devine et al. (2014) evaluated the usability of pharmacogenomic CDS alerts that were already embedded in a CPOE system among a small sample of cardiologists and oncologists. Lærum et al. (2014) developed a prototype for CYP3A5-based treatment during kidney transplantation and evaluated it among a small sample of hospital physicians. Both studies found that the physicians' attitude towards clinical implementation of pharmacogenetics-based therapy by means of a CDS system was positive. Furthermore, both studies emphasized physicians' preferences for seeing essential results and recommendations right away, with further explanations and references easily accessible but separated in order to prevent distraction from essential information needed for quick decision-making. In a recent study Overby et al. (2015) examined the impact of physicians characteristics (e.g., awareness and previous experience) on the communication effectiveness (i.e., changes in confidence in prescribing decisions, usefulness) of PGx alerts of a prototypical pharmacogenomics CDS system embedded in an EHR. They did not find any association of previous experience with and awareness of PGx CDS systems with communication effectiveness of PGx alerts among the 22 included physicians. However, they reported a significant decrease of the physicians' confidence in prescribing when presented with active and semi-active alerts generated by their embedded PGx CDS prototype as compared to viewing information on genetic variants prior to ordering a medication. The present study builds on and complements the existing literature by providing insights into the perceptions of an alternative, mobile-based and thus highly flexible way of providing concise PGx clinical decision support that can be deployed in various healthcare settings independent of existing EHRs and CPOEs. Furthermore, while much of the available literature on PGx CDS focuses on how alert messages should be structured and presented, this is the first study to explore ways to alert health care providers without advanced PGx knowledge in clinical and outpatient settings to the availability of essential PGx therapy modifications by means of a personalized pocket card. These findings, furthermore, complement existing research that focuses on patient preferences regarding the storage of pharmacogenomic test results and on the development of patient-friendly genomic test reports to ensure lifelong benefits of pharmacogenomic testing. (Haga et al., 2012, 2011)

## Limitations

A limitation of the study lies in the modest survey response rate of Survey B. This might have led to higher evaluation scores of the MSC system in this part of the study due to the assumable higher fraction of technology enthusiasts among the participating physicians and pharmacists. Furthermore, the study was limited by the fact that the interview transcripts were coded by only one researcher without establishing inter-rater reliability. Coding by more than one researcher would possibly have led to slightly different categorizations. However, it is unlikely that this limitation has substantially and negatively influenced the overall study goal since the aim of the qualitative interviews was to identify broad tendencies rather than detailed lists of concerns. Finally, due to the transnational approach of our study, participants were recruited from very heterogeneous health care systems which might have influenced the evaluation results, especially regarding workflow integration. However, this limitation is at least partly mitigated due to the MSC system's independence of existing health IT infrastructure.

## CONCLUSIONS

This is the first study to examine attitudes towards the usefulness and usability of a flexible mobile-based clinical decision support system for pharmacogenetics-guided drug therapy that can be easily integrated into existing care processes and infrastructures. Our study captures a breadth of viewpoints ranging from PGx experts from various disciplines to physicians and pharmacists without advanced PGx knowledge. Our mixed methods approach allowed for a comprehensive and complementary evaluation of the MSC

system and provided a transnational perspective. Our findings suggest that the very concise presentation of the essential facts and recommendations by the MSC interface is deemed acceptable for guiding clinical decisions and that the system is perceived positively by the physicians and pharmacists included in the study. Our findings also point out that including a list of alternative drugs could help to increase user acceptance of pharmacogenomics CDS systems. Furthermore, this study provides key insights into how human-readable pharmacogenomic information can be used to alert health professionals to the availability of essential therapy modifications for a specific patient. A gene-centered and tabulated presentation of the patient's pharmacogenomic profile along with a listing of critically affected drugs is deemed most useful by professionals. The results of this study will inform the further evolution of the MSC system. Finally, our findings suggest that adequate education about legal and regulatory backgrounds regarding the use of pharmacogenetic information as well as information about the cost-benefit ratio of pharmacogenetic testing will be necessary to achieve optimal user acceptance of pharmacogenomics CDS.

## LIST OF ABBREVIATIONS

**CDS** Clinical Decision Support

**CPIC** Clinical Pharmacogenetics Implementation Consortium

**CPOE** Computerized Provider Order Entry

**DPWG** Dutch Pharmacogenetics Working Group

**EHR** Electronic Health Record

**MSC** Medication Safety Code

**PGx** Pharmacogenomics

**QR** Quick Response

**SUS** System Usability Scale

**UI** User Interface

## ACKNOWLEDGMENTS

We thank Professors Harry Hochheiser and Philip E. Empey for providing feedback on the study's design and facilitating contact with pharmacist students for the interviews. Furthermore, we thank Professor Robert R. Freimuth for enabling us to advertise our survey via the AMIA Genomics TBI and PharmGKB networks.

## REFERENCES

- Boyce, R. D., Freimuth, R. R., Romagnoli, K. M., Pummer, T., Hochheiser, H., and Empey, P. E. (2013). Toward semantic modeling of pharmacogenomic knowledge for clinical and translational decision support. *AMIA Joint Summits on Translational Science proceedings AMIA Summit on Translational Science*, 2013:28–32.
- Bright, T. J., Wong, A., Dhurjati, R., Bristow, E., Bastian, L., Coeytaux, R. R., Samsa, G., Hasselblad, V., Williams, J. W., Musty, M. D., Wing, L., Kendrick, A. S., Sanders, G. D., and Lobach, D. (2012). Effect of clinical decision-support systems: a systematic review. *Annals of Internal Medicine*, 157(1):29–43.
- Brooke, J. (1996). Sus: A quick and dirty usability scale.
- Caudle, K. E., Klein, T. E., Hoffman, J. M., Muller, D. J., Whirl-Carrillo, M., Gong, L., McDonagh, E. M., Sangkuhl, K., Thorn, C. F., Schwab, M., Agundez, J. A. G., Freimuth, R. R., Huser, V., Lee, M. T. M., Iwuchukwu, O. F., Crews, K. R., Scott, S. A., Wadelius, M., Swen, J. J., Tyndale, R. F., Stein, C. M., Roden, D., Relling, M. V., Williams, M. S., and Johnson, S. G. (2014). Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. *Current drug metabolism*, 15(2):209–217.

- 510 Devine, E. B., Lee, C.-J., Overby, C. L., Abernethy, N., McCune, J., Smith, J. W., and Tarczy-Hornoch, P.  
511 (2014). Usability evaluation of pharmacogenomics clinical decision support aids and clinical knowledge  
512 resources in a computerized provider order entry system: a mixed methods approach. *International*  
513 *Journal of Medical Informatics*, 83(7):473–483.
- 514 Gottesman, O., Scott, S. A., Ellis, S. B., Overby, C. L., Ludtke, A., Hulot, J.-S., Hall, J., Chatani, K., Myers,  
515 K., Kannry, J. L., and Bottinger, E. P. (2013). The CLIPMERGE PGx Program: clinical implementation  
516 of personalized medicine through electronic health records and genomics-pharmacogenomics. *Clinical*  
517 *pharmacology and therapeutics*, 94(2):214–217.
- 518 Haga, S. B., Burke, W., Ginsburg, G. S., Mills, R., and Agans, R. (2012). Primary care physicians’  
519 knowledge of and experience with pharmacogenetic testing. *Clinical Genetics*, 82(4):388–394.
- 520 Haga, S. B., Kawamoto, K., Agans, R., and Ginsburg, G. S. (2011). Consideration of patient preferences  
521 and challenges in storage and access of pharmacogenetic test results. *Genetics in Medicine: Official*  
522 *Journal of the American College of Medical Genetics*, 13(10):887–890.
- 523 Hoffman, J. M., Haidar, C. E., Wilkinson, M. R., Crews, K. R., Baker, D. K., Kornegay, N. M., Yang, W.,  
524 Pui, C.-H., Reiss, U. M., Gaur, A. H., Howard, S. C., Evans, W. E., Broeckel, U., and Relling, M. V.  
525 (2014). PG4kds: A model for the clinical implementation of pre-emptive pharmacogenetics. *American*  
526 *journal of medical genetics. Part C, Seminars in medical genetics*, 166(1):45–55.
- 527 Jaspers, M. W. M., Smeulders, M., Vermeulen, H., and Peute, L. W. (2011). Effects of clinical decision-  
528 support systems on practitioner performance and patient outcomes: a synthesis of high-quality system-  
529 atic review findings. *Journal of the American Medical Informatics Association: JAMIA*, 18(3):327–334.
- 530 Kawamoto, K. (2005). Improving clinical practice using clinical decision support systems: a systematic  
531 review of trials to identify features critical to success. *BMJ*, 330(7494):765–0.
- 532 Lala, A., Berger, J. S., Sharma, G., Hochman, J. S., Scott Braithwaite, R., and Ladapo, J. A. (2013). Genetic  
533 testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a  
534 cost-effectiveness analysis. *Journal of thrombosis and haemostasis: JTH*, 11(1):81–91.
- 535 Lee J. Cronbach (1951). Coefficient alpha and the internal structure of tests. *Psychometrika*, (Volume  
536 16):pp 297–334.
- 537 Lærum, H., Bremer, S., Bergan, S., and Grünfeld, T. (2014). A taste of individualized medicine:  
538 physicians’ reactions to automated genetic interpretations. *Journal of the American Medical Informatics*  
539 *Association: JAMIA*, 21(e1):e143–146.
- 540 Miñarro-Giménez, J. A., Blagec, K., Boyce, R. D., Adlassnig, K.-P., and Samwald, M. (2014). An  
541 ontology-based, mobile-optimized system for pharmacogenomic decision support at the point-of-care.  
542 *PloS One*, 9(5):e93769.
- 543 O’Donnell, P. H., Danahey, K., Jacobs, M., Wadhwa, N. R., Yuen, S., Bush, A., Sacro, Y., Sorrentino,  
544 M. J., Siegler, M., Harper, W., Warrick, A., Das, S., Saner, D., Corless, C. L., and Ratain, M. J. (2014).  
545 Adoption of a clinical pharmacogenomics implementation program during outpatient care—initial results  
546 of the University of Chicago “1,200 Patients Project”. *American Journal of Medical Genetics. Part C,*  
547 *Seminars in Medical Genetics*, 166C(1):68–75.
- 548 Olgiati, P., Bajo, E., Bigelli, M., De Ronchi, D., and Serretti, A. (2012). Should pharmacogenetics  
549 be incorporated in major depression treatment? Economic evaluation in high- and middle-income  
550 European countries. *Progress in neuro-psychopharmacology & biological psychiatry*, 36(1):147–154.
- 551 Overby, C. L., Devine, E. B., Abernethy, N., McCune, J. S., and Tarczy-Hornoch, P. (2015). Making  
552 pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians.  
553 *Journal of Biomedical Informatics*, 55:249–259.
- 554 Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., Kesteven, P.,  
555 Christersson, C., Wahlström, B., Stafberg, C., Zhang, J. E., Leathart, J. B., Kohnke, H., Maitland-  
556 van der Zee, A. H., Williamson, P. R., Daly, A. K., Avery, P., Kamali, F., Wadelius, M., and EU-PACT  
557 Group (2013). A randomized trial of genotype-guided dosing of warfarin. *The New England journal of*  
558 *medicine*, 369(24):2294–2303.
- 559 Pulley, J. M., Denny, J. C., Peterson, J. F., Bernard, G. R., Vnencak-Jones, C. L., Ramirez, A. H., Delaney,  
560 J. T., Bowton, E., Brothers, K., Johnson, K., Crawford, D. C., Schildcrout, J., Masys, D. R., Dilks,  
561 H. H., Wilke, R. A., Clayton, E. W., Shultz, E., Laposata, M., McPherson, J., Jirjis, J. N., and Roden,  
562 D. M. (2012). Operational Implementation of Prospective Genotyping for Personalized Medicine: The  
563 Design of the Vanderbilt PREDICT Project. *Clinical Pharmacology & Therapeutics*, 92(1):87–95.
- 564 Samwald, M. and Adlassnig, K.-P. (2013). Pharmacogenomics in the pocket of every patient? A prototype

- 565 based on quick response codes. *Journal of the American Medical Informatics Association: JAMIA*,  
566 20(3):409–412.
- 567 Schildcrout, J. S., Denny, J. C., Bowton, E., Gregg, W., Pulley, J. M., Basford, M. A., Cowan, J. D., Xu,  
568 H., Ramirez, A. H., Crawford, D. C., Ritchie, M. D., Peterson, J. F., Masys, D. R., Wilke, R. A., and  
569 Roden, D. M. (2012). Optimizing drug outcomes through pharmacogenetics: a case for preemptive  
570 genotyping. *Clinical pharmacology and therapeutics*, 92(2):235–242.
- 571 Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., Rongen, G.  
572 A. P. J. M., van Schaik, R. H. N., Schalekamp, T., Touw, D. J., van der Weide, J., Wilffert, B., Deneer,  
573 V. H. M., and Guchelaar, H.-J. (2011). Pharmacogenetics: from bench to byte—an update of guidelines.  
574 *Clinical pharmacology and therapeutics*, 89(5):662–673.
- 575 Thompson, A. J., Newman, W. G., Elliott, R. A., Roberts, S. A., Tricker, K., and Payne, K. (2014).  
576 The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for  
577 azathioprine. *Value in health: the journal of the International Society for Pharmacoeconomics and*  
578 *Outcomes Research*, 17(1):22–33.
- 579 Tuteja, S., Haynes, K., Zayac, C., Sprague, J. E., Bernhardt, B., and Pyeritz, R. (2013). Community  
580 pharmacists’ attitudes towards clinical utility and ethical implications of pharmacogenetic testing.  
581 *Personalized Medicine*, 10(8).
- 582 Varonen, H., Kortteisto, T., Kaila, M., and EBMeDS Study Group (2008). What may help or hinder  
583 the implementation of computerized decision support systems (CDSSs): a focus group study with  
584 physicians. *Family Practice*, 25(3):162–167.
- 585 Verhoef, T. I., Redekop, W. K., de Boer, A., Maitland-van der Zee, A. H., and EU-PACT group (2015).  
586 Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The  
587 Netherlands. *Pharmacogenomics*, 16(2):101–114.
- 588 Walji, M. F., Kalenderian, E., Piotrowski, M., Tran, D., Kookal, K. K., Tokede, O., White, J. M.,  
589 Vaderhobli, R., Ramoni, R., Stark, P. C., Kimmes, N. S., Lagerweij, M., and Patel, V. L. (2014). Are  
590 three methods better than one? A comparative assessment of usability evaluation methods in an EHR.  
591 *International Journal of Medical Informatics*, 83(5):361–367.
- 592 Zaidi, S. T. R., Marriott, J. L., and Nation, R. L. (2008). The role of perceptions of clinicians in their  
593 adoption of a web-based antibiotic approval system: do perceptions translate into actions? *International*  
594 *Journal of Medical Informatics*, 77(1):33–40.